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Abstract: The role of phytochemicals as potential prodrugs or therapeutic substances against tumors
has come in the spotlight in the very recent years, thanks to the huge mass of encouraging and
promising results of the in vitro activity of many phenolic compounds from plant raw extracts
against many cancer cell lines. Little but important evidence can be retrieved from the clinical
and nutritional scientific literature, where flavonoids are investigated as major pro-apoptotic and
anti-metastatic compounds. However, the actual role of these compounds in cancer is still far
to be fully elucidated. Many of these phytochemicals act in a pleiotropic and poorly specific
manner, but, more importantly, they are able to tune the reactive oxygen species (ROS) signaling to
activate a survival or a pro-autophagic and pro-apoptosis mechanism, depending on the oxidative
stress-responsive endowment of the targeted cell. This review will try to focus on this issue.
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1. Introduction
The ability of phytochemicals to prevent cancer has been long claimed as the most outstanding
potential of these plant-derived molecules, despite the fact that quite the whole bulk of these substances
is made of toxic compounds [1–4]. However, the purported anticancer activity of many phenolics
produced in the natural world, accounting for more than 5000 different chemically characterized
compounds in edible plants [5], has been reported to fundamentally depend on their antioxidant
property [6]. Notwithstanding, the ability of phytochemicals to induce the expression of the Nrf2-ARE
signaling pathway [7–9], despite the evidence that all stressors can activate the Nrf2-ARE system [10],
the potential of these plant-derived phenolic substances to promote, enhance and trigger the
expression and the activity of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxydase
(GPX) [11], represent a fundamental hallmark to trust these substances as possible chemopreventive
molecules [12–16]. How phytochemicals can counteract tumors is still far to be fully elucidated.
Phytochemicals have a huge panoply of intracellular targets and their interaction with many of
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them is yet puzzling to date and particularly intriguing [17]. A first issue to be focused on is the
relationship between mitochondria, reactive oxygen species (ROS) and cancer [18–21]. Plant-derived
phytoestrogens, such as catechins, can induce mitochondrial biogenesis, thus restoring mitochondria
function, via the induction of survival signaling systems activated during mitohormesis, such as
AMPK/AAK-2, SIRT1/SIR-2.1 and FOXO/DAF-16, in C. elegans [22]. Targeting mitochondria should
demonstrate also the ability of these molecules to tune cell morphogenesis and improve mitochondria
function and biogenesis [23–25]. Actually, alterations in the mitochondrial dynamics modulate
some type of tumors. For example, the dysregulated mitochondrial fusion by Mfn2 knockdowns
suppresses the rate of oxygen consumption in melanoma cells, suggesting that mitochondrial
dynamics, i.e., the rate of fission and fusion, modulate cell migration and progression in this type of
cancer [26]. Dihydromyricetin is able to reverse mitochondrial dysfunction, which should be mediated
by PGC-1α/TFAM and PGC-1α/mfn2 signaling pathways, therefore ameliorating mitochondria
dynamics [27]. Mitochondria dysfunction is a typical hallmark of many cancers and the ability of
phytochemicals to restore it appears quite fundamental [28–30]. The fìne regulation of the survival
process in a cell involves a series of signaling pathways that not only encompasses the enzymatic
endowment for ROS scavenging but also the complex machinery modulation of the crosstalk between
mitochondria and other organelles leading to the autophagy/apoptosis balance [31–33].
The role of phytochemicals in this context is particularly interesting [34,35].
Phytochemicals not only may counteract cancer malignancy and progression but can induce
tumor cells necroptosis, besides apoptosis [36,37]. Furthermore, the role of autophagy in cancer
development has been extensively reviewed in recent years [38]. Although autophagy would lead
to a suppression of tumorigenesis, some circumstances showed an opposite action on cancer [38,39].
Therefore, the ability of phytochemicals to target cellular autophagy as an approach in using the natural
substances as chemopreventive compounds should be considered with particular attention, despite the
many encouraging results [40–42]. Their activity might also target intracellular calcium signaling and
endoplasmic reticulum (ER) stress [43,44], which exerts a major role in the mitochondria-mediated
tuning of the many cell survival functions [45]. A role in maintaining the mitochondria–ER stress
homeostasis has been recently attributed to Lon proteases (LONPs), where LONP is a protein complex
made by a homo-hexameric ring-shaped structure with a serine–lysine catalytic dyad, which is highly
conserved in both prokaryotic and eukaryotic organisms [46,47]. LONPs are upregulated during
ER stress, via the activation of the PERK-ATF4 signaling pathway [48,49], which may be targeted by
flavonoids [50–52]. In this perspective, plant-derived polyphenols might target many anti-oxidant
cell signaling systems, which exert a major role in mitochondria biogenesis and mitochondria–ER
stress homeostasis. The close interaction between mitochondria and ER may be regulated by
caveolin-1, which is located at the mitochondria/ER interface where it impairs the remodeling of the
mitochondria–ER relationship by making mitochondria non responsive to ER stress via the dampening
of the calcium signaling [53,54]. This mechanism is counterbalanced by the PKA-DRP1-mediated
signaling [54,55], which is targeted by flavonoids [56]. In cancer cells, this homeostasis can be
profoundly perturbed and the activity of flavonoids can be functionally inverted with respect to
the one acting on normal, non-cancerous cells [57]. Actually, tumors have a different stress response
with respect to non tumoral cells, so that any therapic approach must take into account this issue [58,59].
In this review, we will attempt to elucidate the very recent novelties in the field of cancer
prevention and therapy using nature-derived phytochemicals.
2. Insights on the Role of Flavonoids in Cancer
2.1. Flavonoids and Apoptosis
Table 1 summarizes some of the very recent results about the flavonoids ability in inhibiting
cancer development and malignancy [60–87]. Many of these molecules act against cancer cells by
promoting and activating apoptosis. The signaling pathways through which flavonoids induce
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apoptosis in cancerous cells are various. Besides the effect on Bax, Bcl-2 and caspases, a further
possibility is represented by the inhibition of fatty acid synthase (FAS) exerted by a great number
of flavonoids, such as epigallocatechin-3-gallate (EGCG), luteolin, quercetin, kaempferol, apigenin,
and taxifolin, which exert their anti-lipogenic activities against many human tumors [88,89]. FAS is
over-expressed in many human epithelial cancers and also in breast tumors. Its inhibition, causing the
accumulation of malonyl-CoA, leads to the upregulation of ceramide levels and the inhibition of
carnitine palmitoyltransferase-1, therefore inducing the expression of the pro-apoptotic genes BNP3,
TRAIL and DAPK2 and causing apoptosis [90]. Interestingly, FAS inhibition causes a massive ROS
upregulation, which has been reported as a key factor in promoting cancer cell apoptosis, curiously
suggesting that antioxidants promote oxidative stress to kill cancerous cells [91]. Actually, flavonoids
inhibit apoptosis in non cancerous cells, probably because of their induction of eustress and hence of
the survival response from cells [17,92], a mechanism closely depending on the flavonoids dose [93]
and their interaction with ROS as signaling molecules [17,94]. Cancer cells are characterized by a high
degree of oxidative stress and ROS production, and they possess a high metabolic and peroxysomal
activity, often leading to mitochondrial dysfunction and an enhanced activity of lypooxygenases,
thymidine phosphorylases, oxydases and cyclooxygenases [95]. However, despite the expected
need in ROS scavenging enzymes, flavonoids exert their anticancer activity very rarely with the
sole increase in the anti-oxidant machinery. More complex coupled mechanisms would occur. For
example, esculetin and quercetin act finely tuning the redox homeostasis in NB4 leukemia cells [96].
Paradoxically, 25 µM quercetin increased NF-κB p65 in the nucleus and reduced it in the cytosol,
whereas it reduced Nrf2 in the nucleus and enhanced it in the cytosol [96]. Furthermore, esculetin,
in contrast with quercetin, increases the level of the superoxide dismutase (SOD) expression [96].
A fine tuning in the cell, where flavonoids may exert an apparently contradictory action, does exist.
Moreover, the hypothesis that cancer might be closely associated with an imbalance in the energy
homeostass, therefore including also ROS signaling and mitochondria oscillation, has been recently
addressed [17,97].
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Table 1. Some of the very recent examples of the roles exerted by flavonoids in cancer cells.
Classification Compound Activity References
Flavones
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Apigenin  Anticancer activity via the Wnt/β-catenin pathway and JAK-STAT. Induction of apoptsis in TRAIL-
resistant cancers 
[60–64] 
Luteolin 
 Induction of apoptosis and autophagy in ANA-1 cells via the p38, JNK and Akt signaling pathways, 
inhibiting Bcl-2 and beclin-1 and activating caspase-3 and caspase-8 
 Proliferation of BT474 and MCF-7 breast cancer cells 
 Apoptosis in BT474 and MCF-7 breast cancer cells 
 Apoptosis in ACS gastric cancer 
Tangeritin  Cell cycle in MCF7 and MDA-MB-468 breast cancer cells via the CYP1A1/CYP1B1-mediated metabolism 
Flavonols 
 
Quercetin  Many types of cancer via apoptosis and inhibition of cell replication 
[41,65–71] 
Kaempferol 
 Apoptosis and autophagy in human lung cancer cells A549 via upregulation of miR-340 
 Apoptosis in HCT116, HCT15, and SW480 colorectal cancer cells 
Myricetin  Prostate cancer cell metastasis by cytotoxic activity 
Fisetin  Growth and metastasis and EMT in MDA-MB-231 and BT549 breast cancer cells 
Galangin  Proliferation of human kidney A498 cancer cells by the induction of apoptosis-targeted PI3K/Akt/mTOR signaling 
Isorhamnetin  Growth of MCF-7 breast cancer cells 
Flavanones (citrus fruit 
flavonoids) 
 
Hesperetin  Apoptosis in H522 lung cancer cells 
[72,73] 
Naringenin  Prostate cancer metastasis via voltage-gated sodium channel blockage 
Flavanonols 
 
Taxifolin  Mammary carcinogenesis via the LXR-mTOR/Maf1/PTEN axis and the CYP1A1- and CYP1B1-mediated 
cancer 
[74,75] 
Flavans (Flavanols) 
Green tea catechins 
Epigallocatechingallate 
(EGCG) 
 Chemoprevention in glioblastoma 
[76–80] 
 Apoptosis in chronic myeloid leukemia by Bcr/Abl-mediated p38-MAPK/JNK and JAK2/STAT3/AKT 
signaling 
Catechin, EGCG  Lung tumor growth via the inhibition of programmed cell death-ligand1 (PD-L1) 
(ECG)  LNCaP and PC-3 prostate cancer cell growth 
Epigallocatechin (EGC)  Suppression of HPV and tumors with curcumin and resveratrol 
Apigenin ↑ Anticancer activity via the Wnt/β-catenin pathway and JAK-STAT. Induction ofapoptsis in TRAIL-resistant cancers
[ 0–64]Luteolin
↑ Induction of apoptosis and autophagy in ANA-1 cells via the p38, JNK and Aktsignaling pathways, inhibiting Bcl-2 and beclin-1 and activating caspase-3 and caspase-8
↓ Proliferation of BT474 and MCF-7 breast cancer cells
↑ Apoptosis in BT474 and MCF-7 breast cancer cells
↑ Apopto is in ACS gastric cancer
Tangeritin ↓ Cell cycle in MCF7 and MDA-MB-468 breast cancer cells via theCYP1A1/CYP1B1-mediated metabolism
Flavonols
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Taxifolin ↓ Mammary carcinogenesis via the LXR-mTOR/Maf1/PTEN axis and the CYP1A1- andCYP1B1-mediated cancer [74,75]
Int. J. Mol. Sci. 2018, 19, 3568 5 of 24
Table 1. Cont.
Classification Compound Activity References
Flavans (Flavanols)
Green tea catechins
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 Apoptosis and EMT in human osteosarcoma cell lines via the ERK2/p38MAPK pathway 
Isoflavonoids Genistein  Apoptosis in Mcl1 human laryngeal cancer cells 
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  Proliferation of EP3-expressing melanoma 
  Alters epigenetic in MDA-MB-231 breast cancer cells 
Daidzein  Apoptosis in colon cancer cells 
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↑ Chemoprevention in glioblastoma
[76–80]
↑ Apoptosis in chronic myeloid leukemia by Bcr/Abl-mediated p38-MAPK/JNK andJAK2/STAT3/AKT signaling
Catechin, EGCG ↓ Lung tumor growth via the inhibition of programmed cell death-ligand1 (PD-L1)
Epicatechin-3-O-gallate (ECG) ↓ LNCaP and PC-3 prostate cancer cell growth
Epigallocatechin (EGC) ↓ Suppression of HPV and tumors with curcumin and resveratrol
Anthocyanidins
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  5 of 23 
 
 
Anthoc ins 
 
Cyanidin 
 
Delphinidin 
 
Angiogenesis in breast cancer via the STAT3/VEGF pathway and miR124 mediated STAT3 
downregulation 
 
[81–83]   
 Apoptosis and autophagy in HER-2 positive breast cancer MDA-MB-453 and BT474 cells 
  
 Apoptosis and EMT in human osteosarcoma cell lines via the ERK2/p38MAPK pathway 
Isoflavonoids Genistein  Apoptosis in Mcl1 human laryngeal cancer cells 
[84–87] 
  Proliferation of EP3-expressing melanoma 
  Alters epigenetic in MDA-MB-231 breast cancer cells 
Daidzein  Apoptosis in colon cancer cells 
Dow arrows = inhibition; Top arrows: activation and/or promotion. Red colours in chemical formulas indicate the typical functional groups and/or chemical 
positions for typical attachments of substituents (isoflavonoids). 
Cyanidin
Delphinidin
↓ A giogenesis in breast cancer via the STAT3/VEGF pathway and miR124 mediatedSTAT3 downregulation
[81–83]↑ Apoptosis and autophagy in HER-2 positive breast cancer MDA-MB-453 and BT474cells
↑ Apoptosis and EMT in human osteosarcoma cell lines via the ERK2/p38MAPKpathway
Isoflavonoids
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  5 of 23 
 
 
Anthocyanidins 
 
Cyanidin 
 
Delphinidin 
 
Angiogenesis in breast cancer via the STAT3/VEGF pathway and miR124 mediated STAT3 
downregulation 
 
[81– 3]   
 Apoptosis and autophagy in HER-2 positive breast cancer MDA-MB-453 and BT474 cells 
  
 poptosis and EMT in human osteos r oma cell lines via the ERK2/p38MAPK pathway 
Isoflavo  Genistein  Apoptosis in Mcl1 human laryng al cancer cells 
[84–87] 
  Proliferatio  of EP3-expressing melanoma 
  Alters epigenetic in MDA-MB-231 breast cancer cells 
Daidzein  Apoptosis in colon cancer cells 
Dow arrows = inhibition; Top arrows: activation and/ r promotion. Red colours in chemical formulas indicate the typical functional groups and/or chemical 
positions for typical attachments of substituents (isoflavonoids). 
Genistein ↑ Apoptosis i Mcl1 human laryngeal cancer cells
[84–87]
↓ Proliferation of EP3-expressing me anoma
Alters epigenetic in MDA-MB-231 breast cancer cells
Daidzein ↑ Apoptosis in colon cancer cells
Dow arrows = inhibition; Top arrows: activation and/or promotion. Red colours in chemical formulas indicate the typical functional groups and/or chemical positions for typical
attachments of substituents (isoflavonoids).
Int. J. Mol. Sci. 2018, 19, 3568 6 of 24
Most of flavonoids trigger the apoptotic pathways in cancer cells via their fundamental signaling
pathways. The isoflavone analog phenoxodiol induces apoptosis in renal cancer by the inhibition
of the Akt pathway, whereas apoptosis is induced in non cancerous cells by phosphorylation of
Akt [98,99]. The induction of apoptosis in cancer cells via the PI3K/Akt signaling pathway is held
by a wide spectrum of phytochemicals. Luteolin induces a caspase-dependent apoptosis in human
hepatocellular carcinoma by inhibiting the Akt phosphorylation [100], and the flavonol glucoside
icanin (40 µM) induces apoptosis via a ROS-mediated damage on mitochondria membrane potential
by suppressing the PI3K/Akt and STAT3 signaling pathways [101]. Furthermore, baicalein, by acting
on the PI3K/Akt/NF-κB, enhances the sensitivity to cisplatin of A549 lung adenocarcinoma cell
line [102].Flavonoids, acting on cells via the PI3K/Akt pathway, should regulate cell survival and
apoptosis at a post-mitochondrial level, i.e., downstream of the mitochondria cytochrome c release and
before the activation of caspase 9 [103]. ROS have a fundamental role in the Akt-mediated signaling
leading to apoptosis, as they activate the Akt/ASK1/p38MAPK pathway, causing a modulation of
ASK1 dephosphorylation, which subsequently activates p38MAPK and downregulating p21 (Cip1),
leading to apoptosis [104,105]. The ability of flavonoids to cause apoptosis in cancer cells via the Akt
pathway may be paradoxically mediated by a rapid imbalance in the intracellular ROS homeostass
or, more probably, by the complex relationship between ASK1 and NF-κB, where IKK has a major
control on the ASK1-JNK axis, associating IKK with ROS and ER stress [106]. Actually, despite the
previous belief about the general increase in NF-κB expression in cancer, recent reports showed that
tumors differentially express specific subunits of the NF-κB pathway, suggesting the possible existence
of a finely regulated tuning towards apoptosis by different flavonoids in different target cells [107].
Actually, 3,4’,7-O-trimethyl quercetin, a derivative of quercetin, induces apoptosis in ovarian cancer
cell lines CRL-1978, CRL-11731, SK-OV-3, following three different target pathways, depending on the
cell type [108].
The widespread knowledge about flavonoids in cancer is that these compounds are generally
very able to have anti-oxidant and anti-inflammatory activities, to induce ROS-scavenging enzymes
and CYP-mediated detoxyfication, to induce cell cycle arrest, apoptosis and autophagy, and to inhibit
proliferation, migration and malignancy [109]. Apoptosis is generally activated by disturbing the
mitochondria–ER stress balance and ROS homeostasis, accessing this machinery via the inhibition
of many survival pathways. Actually, pathways by which flavonoids induce apoptosis are
altogether related to cell survival processes. Glabridin causes apoptosis in oral cancer cells via
the JNK1/2 pathway, which with NF-κB is involved in cell survival, apoptosis, inflammation and
angiogenesis [110,111]; hesperedin induces apoptosis in endometrial carcinoma by downregulating
the estrogen receptor relationship via the ERK/MAPK pathway [112]; apigenin triggers apoptosis
and autophagy in hepatocellular carcinoma cells via the PI3K/Akt/mTOR signaling pathway [113];
chrysin and other fundamental components of propolis, such as the phenolic acids caffeic, ferulic and
α-coumaric acid, induce a proline dehydrogenase/proline oxidase-dependent apoptosis in human
tnongue squamous cell carcinoma [114]. The panoply of different targets by which flavonoids
induce apoptosis may be a consequence of their modulatory role in balancing the apoptosis/necrosis
ratio [115].
Research on apoptosis and autophagy caused by phytochemicals seems to be mostly polarized on
certain types of cancer, i.e., breast, prostate and colon cancer and more frequently involving curcumin,
flavonoids, and resveratrol [116]. Curcumin and resveratrol also induce apoptosis via the same survival
pathways targeted by several flavonoids, e.g., PI3K/Akt [117,118], MAPK/JAK2/STAT3 [119,120],
p38MAPK/ERK1/2/JNK [121,122], Wnt/β-catenin [123,124], NF-κB [125,126]. Besides these major
pathways, phytochemicals are able to induce apoptosis in cancer cells, targeting many further signaling
and biochemical mechanisms. For example, resveratrol is able to target cellular FLICE-inhibitory
protein (c-FLIP), which is a master tuner in the inhibition of apoptosis with the death receptors
TNF-R1, Dr5, DR4 and Fas. In lung cancer cells, resveratrol causes p-Akt and c-FLIP downregulation,
inducing apoptosis along with an increase in the production of ROS and hydrogen peroxide-elicited
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Bid, activation of PARP and caspase 8, and downregulation of pEGFR and NF-κB protein
expression [127,128].
The most common route through which flavonoids induce apoptosis in cancer cells, i.e.,
the PI3K/Akt pathway, is probably the major signaling mechanism leading to cell survival
gene expression with different approaches, e.g., PI3K/Akt/Raf1/MEK/ERK [129,130], PI3K/Akt/
mTOR [131], and PI3K/Akt/ERK1-2/NF-κB [132]. Furthermore, the flavonoid irigenin targets
the TRAIL signaling pathway leading to apoptosis in gastric cancer, with the enhancement of
FAS-associated protein with death domain (FADD), death receptor 5 (DR5) and Bax proapoptotic
proteins [133], a way targeted also by pinostrobin [134], apigenin [135], kaempferol [136].
Figure 1 shows the major pathways targeted by flavonoids, coumarins and stilbenes (resveratrol)
in inducing apoptosis in cell cancer.
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2.2. Autophagy and the Mitochondria–ER Stress Relatonships Leading to Cancer Cell Death
Flavonoids can target the autophagic machinery in cancer cells, so managing and ruling
the survival homeostatic processes yet often leads to the apoptotic destiny of tumoral cells [116].
For example, kaempferol induces autophagy to upregulate miR-340 in human lung cancer cells [41]
also via the IRE-JNK-CHOP pathway [137]. The widest activity of flavonoids on apoptosis in cancer
cells via the major survival signaling pathways would raise the question about which relationship does
exist between autophagy and apoptosis [138], although a fundamental link with the Akt signaling
pathway has been recently highlighted [139] and some major components of the fission and fusion
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machinery in mitochondria, i.e., dynamin-related protein 1 (Drp1), mitofusin1/2 (Mfn1/2) and
Optic Atrophy 1 (OPA1), were reported to be involved in the mitochondria-related modulation
of autophagy, besides apoptosis and necroptosis [140]. Flavonoids might act in the crosstalk leading to
the autophagy–survival mechanism or the autophagy–apoptosis decision [141–143], where a possible
role is exerted by beclin-1, Bcl-2 and Bcl-xL [144,145]. Furthermore, the regulation of mitophagy and
autophagy depends on acetylation (see acetylCoA) and Lys acetylation in mitochondria, accounting for
a stringent control in nutrients uptake [146,147]. Autophagy can participate in cancer eradication;
for example, silibinin induces MCF7 breast cancer cells death via the upregulation of beclin-1 and
Atg12–Atg5 formation, the conversion of the light chain 3 (LC3)-I to LC3-II, mitochondrial leakage of
the mitochondrial transmembrane potential and a decline in ATP levels, together with a great increase
in ROS [148].
The role of autophagy in cancer has been extensively reviewed [149,150]. Autophagy is a
key regulator of cell survival and homeostasis and past reports suggested its role as a tumor
suppressor. However, a hypothesis by which autophagy leads to tumorigenesis has been related
to its reduction in the stress response capability, thus leading to much more support in cell metabolism
and survival processes [149]. Cancer cells are more dependent on autophagy than other cells.
The abnormal increase in the metabolic demand shifts the autophagy towards mechanisms, leading to
apoptosis or cell cycle arrest. Particularly for RAS-driven cancers, recent reports suggest that they
are “autophagy-addicted” [151,152]. Interestingly, the flavonoid 6-C-(E-phenylethenyl)naringenin
(6-CEPN), which can be found in naringenin-fortified fried beef, induces cytoprotective autophagy
in colon cancer cells, although it inhibits cell growth by dampening the expression of autophagy
proteins Atg7 and beclin-1. The compound 6-CEPN strongly activates RAS [153]. Further flavonoids
kill cancer cells via an autophagic signaling pathway. The flavone isoorientin induces autophagy
in hepatoblastoma cancer, activating ROS signaling leading to p53 expression and so concurrently
activates apoptosis by the PI3K/Akt, JNK and p38MAPK signaling pathways [154]. The induction of
ROS signaling to result in cancer cell apoptosis, via the initial autophagic process, has been reported
also for the flavonoid wogonoside in human glioblastoma cells [155]. Interestingly, it seems that
flavonoids do not exert their acknowledged antioxidant potential in cancer; however, a possible reason
is that they shift the hormetic curve of survival homeostasis in cancer towards an autophagy-driven
apoptotic signal, instead of an autophagy-driven survival process.
Possible sensitive targets of this “pro-oxidant” flavonoids-mediated mechanism are mitochondria,
often in association with ER stress and the unfolded protein response (UPR) [156].
The prenylated flavonoid morusin induces an increase in the levels of mitochondrial calcium ions,
with ER stress, induction of ROS and loss of mitochondrial membrane potential in epithelial ovarian
cancer [157]. Calcium overload in mitochondria induces mitochondrial swelling and dysfunction,
leading to morusin-induced paraptosis-like cell death [157]. Paraptosis is a mechanism leading to
tumoral cell death, which is different from apoptosis and necrosis [158]. Some flavonoids induce
paraptosis in cancer cells. For example, the polyphenol xanthohumol induces paraptosis in leukemia
cells via the p38MAPK pathway [159], hesperidin, likewise morusin, causes paraptosis in HepG2
cells by inducing mitochondria calcium overload and subsequently mitochondria dysfunction [160].
Moreover, a possible finely controlled tuning of the cell survival/cell death homeostasis should explain
terms such as paraptosis and necroptosis and their relationship with autophagy [161].
Flavonoids might work in the crosstalk between survival and cell death, acting either as
anti-oxidant or pro-oxidant molecules, depending on the stress-responsive endowment of the
perturbed cell. Certainly, the mitochondrial/ER proteasome orchestrated function may play a major
role [17,53,162–165].
2.3. Epithelial Mesenchymal Transition (EMT) and Cell Cycle Arrest
Many phytochemicals, such as flavonoids, induce cancer cell death by targeting the cellular
EMT pathways. Nobiletin, a hexamethoxyflavone, inhibits the EMT process initiated by hypoxia in
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renal cell carcinoma via the NF-κB and the Wnt/β-signaling pathways, dampening cancer migration
and invasion (malignancy) [166]. The effect on EMT and therefore on cancer migration can be also
associated with the induction of apoptosis [167] and even initially targeting the same signaling
systems then leads to apoptosis, such as the Akt-related pathways. For example, apigenin inhibits
non-small cell lung cancer metastasis by dampening the EMT signal via a CD26-Akt-Snail/Slug
signaling pathway [168]. Furthermore, the PI3K/Akt signaling pathway can lead to cell cycle arrest in
cancer [101]. The chalconoid cardamonin induces apoptosis and cell cycle arrest in breast cancer by
downregulating Wnt3a/β-catenin induction of EMT, blocking EMT and dampening the metastatic
signal [169]. Despite the attempt to induce cell survival, for example, by phosphorylating some
signaling molecules, such as ERK, cancer cells can undergo cytotoxicity from flavonoids, which
inhibits EMT-driven metastasis and blocks cell cycle [170]. The activity held by phytochemicals
is fundamentally made of a pro-toxicant nature; normal cells have the ability to counteract their
pro-oxidant potential, whereas cancer cell do not.
ROS are closely associated with EMT in cells and redox regulation in the EMT-related cancer
progression is an issue of utmost interest [171–173]. One could think that flavonoids may even “use”
their antioxidant ability to inhibit the ROS-induced EMT in cancer. However, it has been recently
reported that superoxide dismutase promotes EMT, enhancing tumor metastasis, in pancreatic cancer
cells via the H2O2/ERK/NF-κB signaling axis [174]. It is particularly difficult to associate flavonoids
with their chemopreventive and anticancer potential by simply retrieving this relationship from their
widely reported antioxidant ability. A possible master tuner is the mitochondria oscillatory balance
of their biogenesis, which rules any survival control and also affects EMT [175–177]. ROS might
exert a fundamental role in balancing signals. When cells are metabolically stressed and are driven
towards mitochondria impairment, risk of mitochondria calcium overload, ER stress with UPR and
so on, mild stress with ROS should work as a signal to induce survival but simply block or interrupt
the autophagy, mitophagy or EMT pathway, leading to apoptosis or cell cycle arrest. When cell
metabolism and bioenergetics are homeostatically controlled, mild ROS induces the survival process
and restore the homeostatic balance. In the case of cancer cells, the homeostatic response is held by an
unusual autophagy–survival relationship driven by ROS distress and by EMT. Mild stress (eustress),
breaking down this “insane” equilibrium, should lead to cell death and EMT inhibition.
2.4. Insights into the Capability of Raw Food and Plant Extracts Containing Phytochemicals to Prevent and
Counteract Cancer
Phytochemicals’ ability to counteract cancer has been particularly stressed in current in vitroand
in vivoresearch [178]. The regular intake of food edible plants has been long associated with a reduction
in the risk to develop cancer. A bulk of more than 200 research investigations can be retrieved from
current scientific literature reporting the association between vegetables and fruit intake and the
prevention of the most common and diffused cancers in humans, including the recent extensively
reviewed research [179]. According to this study, the protective effect of plant-derived substances in
daily diet, expressed as relative risk, was assessed for at least 128 of 156 nutritional investigations [179].
For the majority of the investigated cancers, people consuming moderate or poorly enriched diets
with fruits or vegetables underwent a doubled risk to develop cancer compared to people with dietary
habits including plant-derived raw foods, even considering statistics with confounders. In the case
of lung cancer, at least 24 of 25 studies retrieved in the latest years reported protection from plants,
after removing confounders for smoking [179]. About 28 of 29 papers reported that fruit consumption
reduced the incidence of cancers in oral cavity, esophagus and larynx, 26 of 30 papers reported the fruit
consumption decreased the incidence of pancreas and stomach cancer, and 28 of 38 papers revealed
the decrease of bladder cancer and colorectal cancer by fruit intake [179]. Furthermore, about 11 of 13
studies’ results are positive for endometrial, cervix and ovary cancers, while the protective effect of
fruits and vegetables intake was assessed also for breast cancer in a performed meta-analysis [179].
These data suggest that good cancer preventions should ask for the daily intake of plant-derived raw
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food [179]. Despite the many positive and encouraging results in in vitro investigations with purified,
aglycone flavonoids, raw food is endowed with an additive and synergistic action of the many different
phenolic components in the raw matrices, showing a better efficacy in preventing cancer [5].
Flavonoids, as a major class of phenolic compounds, exhibited highly antioxidant activity.
These compounds have been connected to reduce the risk of main chronic diseases and have been
recognized largely in fruits, vegetables, and other plant foods [180]. For example, indigenous
individuals living in Siberian areas possess a typical socio-economical and anthropological tradition,
which allow the people to use a particular kind of diet with plant raw foods. Phenolic, flavonoids,
elements and organic acids content, antioxidant and cytotoxic activity of six Siberian indigenous fruits
have been recently studied [181]. Cell cytotoxicity of the human prostate cancer cell line Du-145
was performed by treating the cell line with at least six different plant extracts of Siberian fruits,
encompassing the concentration range of 0–100 µg/mL. Siberian apricot, Siberian mountain ash and
Siberian bird cherry showed a moderate cytotoxic effect in a dose-dependent fashion. Siberian apricot
extracts caused 50% of the cytotoxic effect at 25 µg/mL and almost a 100% effect at 100 µg/mL [181].
Some enzymes are particularly targeted by flavonoids contained in Siberian fruits. For example,
cyclooxygenases (COXs), which play a major role in inflammatory reactions and carcinogenesis,
besides modulating cell apoptosis, proliferation and the angiogenic mechanisms in tissues, are possible
targets of these flavonoids. For example, anthocyanins in cherry fruits target COXs, exhibiting an
anti-inflammatory activity [182]. Cherry extracts are considered as a good candidate to inhibit COX
proinflammatory and pro-carcinogenetic activities. With their sweet and sour taste, cherry fruits are an
acknowledged food used by Siberian to promote their good health. Cherries contain a huge amount
of anthocyanins and anthcyanidins, mixed with phenolic acids. The frequent and regular intake of
these fruits appears particularly beneficial in reducing the incidence of certain cancers. The study on
lipid peroxidation and on the activity of COXs by flavonoids from different sweet and sour varieties of
Siberian cherries assessed the role of these compunds as natural inhibitors [182]. The role of cherry
anthocyanins for colon cancer prevention was confirmed in another study using a combination of
dietary anthocyanin-rich extract and suboptimal dosages of sulindac in mice for 19 weeks [183]. Cherry
leaves alcohol extract containing flavonoids showed a pronounced anti-inflammatory activity (52.1%),
not inferior to the compared drug quercetin (50.9%) [184].
The cancer suppression activity of peach and plum extracts were also evaluated [185]. It was
found that within all fractions, flavonoids and procyanidins were more potent against the three cell
lines investigated in the study. Quercetin 3β-glucoside was the most bioactive compound identified
in the chromatographic fractions, able to exert an anti-proliferative activity against MDA-MB-435
and MCF-10A breast cancer cell lines [185]. Growth-inhibitory effects were also reported on Caco-2,
SW1116, HT29 and NCM460 cancer cell lines from extracts of plums and peaches notoriously being
enriched with anthocyanins [186]. The most efficacious fraction contained flavonoids rather than
anthocyanins, suggesting that a synergistic activity with phenolics in plum and peaches extracts from
Siberian fruits should explicate the action on cancer cell lines previously observed [186].
Many recent research investigations have shown that phytochemicals in fruits express an
orchestrated panoply of similar actions, often shown as overlapping effects, which include the
regulation of the expression of detoxyfying antioxidant enzyme complexes, activation of innate
immunity, modulation of gene expression, cell replication, autophagy and apoptosis and antimicrobic
activity [5]. Some examples are particularly interesting for the effect of oxidation. Prunus domestica
leaves extract is rich in hydroxycinnamic acids and flavonoids. The extract was tested in vitro and
showed the greatest activity against the suppression of lipid peroxidation. It was found that the extract
reduced the level of peroxidation products by 88.1% [187].
A prospective study, enrolling about 9959 subjects (age: 15–99 years, sex: equally distributed) and
performed in Finland, reported an interesting inverse association between flavonoid assumption with
diets and incidence of cancer [5].
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Following a 24-year follow-up period, researchers reported that the risk of lung cancer was
reduced by 50% (superior quartile of the flavonoid intake amounts). The consumption of quecetin
contained in apples and onions in Hawaii was found to be inversely corelated with the incidence of
lung cancer.
Moreover, the effect of onions intake resulted particularly promising in reducing squamous cell
carcinoma incidence [5]. The increasing plasma levels of quercetin from ingested onions were also
associated with an enhanced resistance to DNA strand breakage occurring in lymphocytes and a
reduction in the level of some catabolites from oxidative stress in urine samples [5].
Further reports showed also that anthocyanins and cyanidins are able to reduce colon cancer
cell lines HT29 and HCT 116 [188]. These studies reported that the 50% inhibitory concentration
(IC50) values of anthocyanins and cyanidins were780 mM and 63 mM for HT29 cells and
285 mM and 85 mM for HCT116 cells, respectively, suggesting that anthocyanins and cyanidins
in cherries may be promising as anticolon cancer natural compounds [188]. Actually, anthocyanidins
counteract a lot of biological mechanisms, leading to cancer aggressiveness, including metastasis and
chemoresistance [189].
Cyanidin is a polyphenolic pigment that can be easily found in many red berries,
including blackberry, grapes, raspberry, cranberry, besides plums, apples and red cabbage and it
is present also in red onions. It has a good potential benefit against cancers, thanks to its antioxidant
property [178]. Cyanidin has been reported to dampen cell proliferation in cancer and to inhibit COX-2
and iNOS gene expression in colon tumors [190–193]. A study showed that cyanidin-3-glucoside
inhibited the benzo[a]pyrene-7,8-diol-9,10-diol-epoxide-induced activation of the transcription factors
AP-1 and NF-κB, including the phosphorylation of MEK, MKK4, Akt and MAPKs [194]. Furthermore,
they also blocked the activation of the Fyn kinase signaling pathway, leading to a chemopreventive
potential [194]. Further flavonoids, such as cyanidin-3-O-glucoside and cyanidin-3-O-rutinoside,
as well as the ethanol extracts of raspberries, caused the inhibition of the cellular growth in highly
tumorigenic rat esophagus cell lines RE-149 DHD but not in the weaker tumorigenic cell line
RE-149 [195]. Further results showed that cyanidin inhibits ultraviolet light B UVB-induced COX-2 and
PGE2 expression in epidermal cells by suppressing the MAPK-mediated NF-κB and AP-1 activity [195].
Furthermore, cyanidin is able to target MKK-4 MEK-1 and Raf-1 in the suppression pathway of
UV-induced COX-2 [195]. Additionally, cyanidin-3-galactoside and cyanidin-3-glucoside are substrates
for BRCP, while cyanidin, cyanidin-3,5-diglucuronide and cyanidin-3-rutinoside are BRCP inhibitors,
although their effect on MDR1 is weak [178,196].
Catechins in green tea represent another hallmark of anticancer flavonoids. Green tea is a very
widespread and commonly used beverage in the world. The majority of anticancer effects from
green tea are attributed to EGCG [197,198]. EGCG is able to kill cancer cells notoriously resistant to
proapoptotic stimuli and induces death through a necroptosis pathway in many cancer [189].
Tea polyphenols can prevent cancer by modulating epigenetic aberrations taking place in DNA
methylation, histone modifications, and microRNAs. By altering these epimutations, they regulate
chromatin dynamics and expression of those genesinducing or suppressing cancer formation [190].
Both theaflavins and thearubigins, which are very abundant polyphenolic compounds in black
tea, possess a strong anticancer potential. Polyphenols in black tea inhibit cell proliferation and trigger
apoptosis in Du 145 prostate cancer cells [191].
Theuse of flavonoids from raw fruits and vegetables should be encouraged with respect to
nutraceutcals from purified active substances [192]. Effects of plant flavonoids on cancer can
be even protective towards cancer cell lines; effects of various polyphenols, such as catechins,
quercetin, flavanones, isoflavones, ellagic acid, lignans, polyphenols from red wine such as resveratrol,
and curcumin, on various type of cancers, including mouth, stomach, duodenum, colon, liver, lung,
mammary gland and skin, were observed [191]. This should account for the bimodal activity held
by flavonoids.
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The flavonol quercetin usually acts as an anticancer molecule via a process that involves the
downregulation of some oncogenes (e.g., Mcl-1, Ras, MEK, P3K) or also the upregulation of some
tumor suppressor genes, leading to the eradication of cancer [193]. Kaempferol, which can be found in
vegetables such as broccoli, tea, grapefruit, Brussels sprouts, witchhazel and apples, has been reported
as efficacious in pancreatic and lung cancer [199–201]. It has antiangiogenic and scavenging effects of
oxygen radicals [178,202–204].
The flavone fisetin, which is present in plants, such as strawberries, persimmon, apples,
Acacia greggii, Acacia berlandieri, Euroasiansmoketree, parrot tree, onion, cucumber and grape, is
a strong antioxidant, modulating protein kinase and lipid kinase pathways [205]. Fisetin has been
found to exert antitumoral actions in HCT-116 colon cancer cell lines [178]. Together with other
flavones and flavonoids such as luteolin, galangin, quercetin and EGCG, fisetin induces the expression
of the Nrf2 factor; moreover, it induces the phase II gene product HO-1 in human retinal pigment
epithelial (RPE) cells. These cells may protect RPE cells from oxidativestress-induced death, with high
efficacy and negligible toxicity [206]. Moreover, itlowered hydrogen peroxide (H2O2)-induced cell
death [189,207].
The isoflavone genistein is present in plants, such as lupine, fava beans, soybeans, kudzu,
and psoralea, Flemingiavestita, and coffee. It is an antioxidant and an anthelmintic, besides exerting
antioxidant effects and antiangiogenic actions (blocking formation of new blood vessels), and also
blocking cell replication and survival [178].
The flavanone naringenin, commonly found in citrus fruit and oranges, besides tomatoes skin
and grapefruit, has a potent antioxidant property [208,209]. It suppresses the TGF-β ligand–receptor
interactions [208], and TGF-β signaling, controlling a various group of cellular mechanisms in cancer,
including cell proliferation, differentiation and apoptosis, as well as morin [189,208,210].
3. Conclusions and Future Remarks
The use of flavonoids and other phytochemicals in cancer research still remains a promising
expectation, despite the many controversial aspects regarding the yet currently paucity in clinical
results. Nutritional panels and dietary guidelines should encourage and support the introduction
of plant phenolics in the daily meal composition, try to possibly reduce the amount of synthetic
nutraceuticals and instead promote raw vegetables and fruit intake. Supplementation may be
desirable if the composition formula is the closest possible with the raw source of the supplemented
phytochemicals, a compulsory item that is very difficult to reach with optimal results. Anyway,
research on flavonoids and plant extracts ensures current pharmacology to find and retrieve new
drugs, able to specifically target cancer cells and to update our therapeutic endowment against
malignancies. The very recent novelties in the field of polyphenol research against cancer refer to not
only microRNA but also long non-coding RNA, such as glyceolinoccurring in soybean [211]. New
fundamental insights in molecular biology of phytochemicals can improve our ability to investigate
and use these compounds against cancer.
One fundamental question could be: why is using flavonoidsmore beneficial than using
chemopreventive drugs against cancer? As a future perspective, flavonoids act as natural molecules,
with surprisingly fewer side effects than chemopreventive drugs. The ability to sensitively tune
fundamental mechanisms in cell survival, autophagy and apoptosis renders these compounds
particularly useful in being adopted as prodrugs and also therapeutic molecules against cancer.
Clinical research must be improved in this sense, in order to retrieve a more and more outstanding
data collection about the excellent ability of these various natural substances to prevent and fight
tumors in humans.
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Abbrevations
AAK Akt-activated kinase
Akt protein kinase B
AMPK adenosine-monophosphate-activated proteinkinase
ARE antioxidant-responsive element
ASK1 apoptosis signal-regulating kinase 1
Atg12–Atg5 autophagy factor12–autophagy factor5
Atg7 autophagy factor 7
Bax Bcl-2-associated X protein
Bcl-2 B-cell lymphoma 2 (an antiapoptotic protein)
Bid BH3-interacting domain
BCRP breast cancer resistance protein
BNP3 Bcl-2-adenovirusE1B 19 kDaprotein-interactingprotein3
6-CEPN 6-C-(E-phenylethenyl)naringenin
Cip1 cyclin-inhibitor protein 1 (p21)
CYP cytochrome P450
DAF16 Dauer-associated factor 16
DAPK2 death-associated protein kinase 2
DRP1 dynamin-related protein 1
ERK extracellularsignal-regulated kinase
FOXO forkhead box O3
HO-1 heme oxygenase 1
IKK IκB kinase
iNOS inducible nitric oxide synthase
IRE-JNK-CHOP
iron response element- Janus kinase-cyclophosphamide-hydroxydaunorubicin-
oncovyn-prednisone)
JAK2 Janus kinase 2
JNK Janus kinase
p38MAPK p38 mitogen-activated protein kinase
MEK a synonymof MAPK
MDR1 multidrug resistant 1
Mfn2 mitofusin-2
mTOR mammalian target of rapamycin
NB4 an acute promyelocytic leukemia cell line
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
Nrf2 nuclear factor erythroid 2-related factor 2
PARP poly-ADP-ribose polymerase
PERK–ATF4 protein kinase RNA-like endoplasmic reticulum kinase–activating transcription factor 4
PGC1α peroxisome proliferator-activated receptor gamma coactivator 1-alpha
PGE2 prostaglandin E2
pEGFR phosphorylated epithelial growth factor receptor
PKA-PI3K protein kinase A-phosphoinositide 3 kinase
Raf1 Ras-associated factor 1
SIR 2-1 sirtuin 2-1
SIRT1 sirtuin 1
Snail/Slug transcription actors in EMT
STAT3 signal transducer and activator of transcription 3
TFAM transcription factor A, mitochondrial
TRAIL TNF-related apoptosis-inducing ligand
Wnt wingless/integrated
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